Yang B C, Virmani R, Nichols W W, Mehta J L
Department of Medicine, University of Florida College of Medicine, Gainesville 32610-0277.
Circ Res. 1993 Jun;72(6):1181-90. doi: 10.1161/01.res.72.6.1181.
Platelets are a source of vasoactive mediators that regulate vascular tone. Platelets also play a role in intravascular thrombus formation and dynamic coronary constriction that result in myocardial ischemia. However, effects of platelets on myocardial function after ischemia and reperfusion are unknown. In this study, we examined the effects of platelets on myocardial dysfunction caused by ischemia/reperfusion. Buffer-perfused isolated rat hearts, after global ischemia (15 minutes) and reperfusion (10 minutes), developed marked myocardial dysfunction, indicated by a 65 +/- 4% decrease in the force of cardiac contraction (FCC) and a 26 +/- 7% increase in coronary perfusion pressure (CPP). Ischemia/reperfusion was also associated with release of creatine kinase (CK) and ATP metabolites in the coronary effluents. Perfusion of hearts with buffer containing washed rat platelets (3-8 x 10(7) cells/ml) protected hearts against dysfunction from ischemia/reperfusion, indicated by minimal changes in CPP (-1 +/- 1%) and FCC (-1 +/- 3%). Release of CK in the coronary effluent was also reduced, as was the release of ATP metabolites in the platelet-perfused hearts. Perfusion of hearts with serotonin receptor antagonist LY53,857 (10(-6) M), thromboxane A2 receptor antagonist SQ29,548 (10(-6) M), adenine nucleotide scavenger apyrase (0.4 units/ml), or nitric oxide synthetase inhibitor NG-monomethyl-L-arginine (2 x 10(-4) M) attenuated (p < 0.05) the platelet-mediated cardioprotective effects. Perfusion of the hearts with L-arginine (2 x 10(-4) M) instead of platelets also showed modest protective effects on FCC (-4.3 +/- 13%), CPP (+18 +/- 7%), and CK release. Prolongation of the ischemic period to 30 minutes and reperfusion to 20 minutes also demonstrated marked cardiac dysfunction (FCC, -58 +/- 10%; CPP, +36 +/- 8%) in buffer-perfused hearts. Perfusion of hearts with platelets in this setting of prolonged ischemia/reperfusion also exhibited protective effects on FCC (-24 +/- 10%), CPP (+12 +/- 6%), and CK release. Thus, platelets protect myocardium from ischemia/reperfusion-induced injury, and these protective effects of platelets are evident regardless of the duration of ischemia/reperfusion. Furthermore, these cardioprotective effects of platelets seem to be related to the release of serotonin, thromboxane A2, and adenine nucleotides. These substances most likely elicit release of endothelium-derived relaxing factor, with its attendant tissue-protective effects, from the microvascular endothelium of hearts.
血小板是调节血管张力的血管活性介质的来源。血小板还在血管内血栓形成和导致心肌缺血的动态冠状动脉收缩中起作用。然而,血小板对缺血再灌注后心肌功能的影响尚不清楚。在本研究中,我们研究了血小板对缺血/再灌注引起的心肌功能障碍的影响。缓冲液灌注的离体大鼠心脏在经历全心缺血(15分钟)和再灌注(10分钟)后,出现明显的心肌功能障碍,表现为心脏收缩力(FCC)降低65±4%,冠状动脉灌注压(CPP)升高26±7%。缺血/再灌注还与冠状动脉流出液中肌酸激酶(CK)和ATP代谢产物的释放有关。用含有洗涤过的大鼠血小板(3 - 8×10⁷个细胞/ml)的缓冲液灌注心脏可保护心脏免受缺血/再灌注引起的功能障碍,表现为CPP(-1±1%)和FCC(-1±3%)变化最小。冠状动脉流出液中CK的释放也减少,血小板灌注心脏中ATP代谢产物的释放同样减少。用5-羟色胺受体拮抗剂LY53,857(10⁻⁶ M)、血栓素A₂受体拮抗剂SQ29,548(10⁻⁶ M)、腺嘌呤核苷酸清除剂Apyrase(0.4单位/ml)或一氧化氮合酶抑制剂NG-单甲基-L-精氨酸(2×10⁻⁴ M)灌注心脏可减弱(p < 0.05)血小板介导的心脏保护作用。用L-精氨酸(2×10⁻⁴ M)代替血小板灌注心脏对FCC(-4.3±13%)、CPP(+18±7%)和CK释放也有适度的保护作用。将缺血时间延长至30分钟并将再灌注时间延长至20分钟时,缓冲液灌注的心脏也表现出明显的心脏功能障碍(FCC,-58±10%;CPP,+36±8%)。在这种长时间缺血/再灌注情况下用血小板灌注心脏对FCC(-24±10%)、CPP(+12±6%)和CK释放也有保护作用。因此,血小板可保护心肌免受缺血/再灌注诱导的损伤, 并且无论缺血/再灌注的持续时间如何,血小板的这些保护作用都是明显的。此外,血小板的这些心脏保护作用似乎与5-羟色胺、血栓素A₂和腺嘌呤核苷酸 的释放有关。这些物质很可能从心脏的微血管内皮引发内皮衍生舒张因子的释放及其伴随的组织保护作用。